1-6 of 6
Gregory P. Donoho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Free
Maxine A. Melchior, Xuemei Guo, Gregory P. Donoho, Philip W. Iversen, Thompson N. Doman, Manisha Brahmachary, Xueqian Gong, Gerald E. Hall, Jason R. Manro, Yung-mae M. Yao, Sean Buchanan, Tod Smeal, Michael D. Kalos, Ruslan D. Novosiadly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B108.
https://doi.org/10.1158/1535-7163.TARG-17-B108
Published: 01 January 2018
View article titled, Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
Journal Articles

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

Free
Michele C. Smith, Mary M. Mader, James A. Cook, Philip Iversen, Rose Ajamie, Everett Perkins, Laura Bloem, Yvonne Y. Yip, David A. Barda, Philip P. Waid, Douglas J. Zeckner, Debra A. Young, Manuel Sanchez-Felix, Gregory P. Donoho, Volker Wacheck
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (10): 2344–2356.
https://doi.org/10.1158/1535-7163.MCT-15-0996
Published: 02 October 2016
View article titled, Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Open the PDF for Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth in another window
Includes: Supplementary data
Journal Articles

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Free
Xiang S. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2463–2472.
https://doi.org/10.1158/1535-7163.MCT-15-0241
Published: 03 November 2015
View article titled, A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Open the PDF for A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models in another window
Includes: Supplementary data
Journal Articles

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Free
Tinggui Yin, Maria J. Lallena, Emiko L. Kreklau, Kevin R. Fales, Santiago Carballares, Raquel Torrres, Graham N. Wishart, Rose T. Ajamie, Damien M. Cronier, Phillip W. Iversen, Timothy I. Meier, Robert T. Foreman, Douglas Zeckner, Sean E. Sissons, Bart W. Halstead, Aimee B. Lin, Gregory P. Donoho, Yuewei Qian, Shuyu Li, Song Wu, Amit Aggarwal, Xiang S. Ye, James J. Starling, Richard B. Gaynor, Alfonso de Dios, Jian Du
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (6): 1442–1456.
https://doi.org/10.1158/1535-7163.MCT-13-0849
Published: 04 June 2014
View article titled, A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Open the PDF for A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models in another window
Includes: Supplementary data
Journal Articles

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Free
Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho, James J. Starling, Enaksha R. Wickremsinhe, Everett J. Perkins, Anne H. Dantzig
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (4): 481–490.
https://doi.org/10.1158/1535-7163.MCT-12-0654
Published: 08 April 2013
View article titled, Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Open the PDF for Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts in another window
Includes: Supplementary data